S t ress hyperglycaemia after acute myocardial infarction: relation to secondary complications and tissue injury (Letter). B r Med J
(1) re p o rted an incre a s e d risk of death among patients with fir s t m y o c a rdial infarction in a population-based study of coro n a ry disease morbidity and mort a l i t y. They comment that some misclassification bias was possible for patients who died, which may have led to an underestimation of the impact of diabetes on subject fatality. Furt h e r, they lightly dismissed the phenomenon of stre s s h y p e rglycemia because they classified all h y p e rglycemic patients diagnosed for the first time during hospitalization for m y o c a rdial infarction as undiagnosed diabetes. Such misclassification would lead to f u rther distortion of the study results. We have shown that hyperglycemia after acute m y o c a rdial infarction is common, and that in most patients it is a temporary phenomenon (2) and is associated with activation of the pituitary adrenal axis (3). However, s t ress hyperglycemia is likely to have been u n d e rre p o rted in the study of Chun et al. because it was population based.
The diagnosis of preexisting diabetes when associated with acute myocard i a l i n f a rction, especially when transient, should be based on additional evidence of hyperglycemia, such as a diabetic glucose tolerance test response or raised HbA 1 c l e v e l .
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N
u m e rous publications are available that address the technical aspects of blood glucose monitoring. However, the practical aspects of self-monitoring the actual metabolic control are less well studied. We have investigated how well patients with type 1 and type 2 diabetes can monitor their blood glucose immediately after participation in a stru c t u re d t reatment and teaching program and some years thereafter (1-3). In a recent population-based public health study aiming at assessment of the degree of diabetes care and education in the geographic area of N o rt h rhine, Germ a n y, we have had the o p p o rtunity to evaluate how well and with which technique randomly selected adult individuals with type 1 diabetes self-monitor their blood glucose (4).
Patients were re c ruited from a random sample of 630 primary care practices by means of a biometrical selection pro c ed u re. All patients were examined at their homes using a mobile ambulance as described previously (5). More than 60% of the patients had participated in a stru ct u red group treatment and teaching program for intensification of insulin therapy.
Of the 684 patients, 402 (59%) were men, and 282 (41%) were women (age 36 ± 11 years, duration of diabetes 18 ± 11 years, HbA 1 c 8.0 ± 1.5% [mean ± SD]). A c a p i l l a ry blood sample was obtained by the patients, using their own method. The accuracy of blood glucose self-measurements was assessed by comparing the value obtained by the patient using his or her own method with a laboratory method. Plasma glucose was measure d immediately in the van with the Reflo t ro n (Boehringer Mannheim, Mannheim, Germany). Data from parallel measure m e n t s a re available from 538 patients (79%). Reasons for the missing parallel measure m e n t s in 146 patients (21%) include the following: 54 patients did not have their glucose monitor with them (8%), 33 patients did not perf o rm self-monitoring (5%), in 17 cases the patient' s glucose monitor was defective (3%), 9 patients declined to perf o rm parallel measurements (1%), in 9 cases no special reasons were given (1%), and in 24 cases the laboratory system was defective (4%).
Of the patients, 88% used a glucose m o n i t o r, and 9% used test strips. 579 patients (85%) re p o rted that they measu red their blood glucose at least twice d a i l y, 463 (68%) re p o rted that they measu red it at least three times daily.
The parallel measurements resulted in an absolute diff e rence of 0.5 ± 1.4 (Ϫ4 . 6 -8.2) mmol/l (mean ± SD [range] ; perc e n tage diff e rence of 8 ± 20% [Ϫ5 4 -1 8 1 % ] ) . The systems used by the patients measu red blood glucose, whereas the laborat o ry system measured plasma glucose. This systematic diff e rence can be assumed to explain the deviation in the re s u l t s . E rror grid analysis showed that 90% of the m e a s u rements were in zone A, with deviations that were clinically not relevant, and 9% were in zone B, with clinically acceptable deviations.
This study shows that nearly all patients had the appropriate material available for self-monitoring of blood glucose. This is in contrast to the results of the Wisconsin study that included 750 type 1 diabetic patients at the 10-year follow-up (6). More than 21% of the participants of that study did not perf o rm self-monitoring, and 24% perf o rmed less than one m e a s u rement per day. At least two measu rements per day were done by only 42% of the patients, in contrast to 85% in our s t u d y. In the present study, the vast majority of the diabetic patients used a glucose monitor for self-monitoring.
The results of this study with a single parallel measurement of blood glucose by the patients and a laboratory method showed that randomly selected diabetic patients with type 1 diabetes do measure their blood glucose with sufficient re l i a b i l i t y. No doubt, insulin analogs are alre a d y contributing to better diabetes care and an i m p roved quality of life for patients with type 1 diabetes. Lispro obviously is off e ring at least these two important characteri s t i c s .
Letters s k o n t rolle der Blutzuckerselbstmessung bei unausgewählten Ty p -I -D i a b e t i k e rn . Dtsch Med Wo c h e n s c h r
N e v e rtheless, we would like to share o b s e rvations on the use of lispro in intensive regimens (three daily premeal injections combined with Ultralente administration before going to bed) in 12 adolescents (14-17 years). Of these 12 patients, five had to re t u rn to their previous intensified insulin regimen of three injections of Regular or Actrapid plus Ultralente within 7-10 days of treatment because of the elevation of their blood glucose 2 h postprandially (180-240 mg/dl).
Because blood glucose levels were perfect (70-110 mg/dl) 1 h after lispro administration and meal ingestion, we thought that dosage increase could be helpful, but this resulted in hypoglycemia.
T h e re f o re, we assumed that the M e d i t e rranean diet, containing larg e amounts of fiber and nutrients with low glycemic indexes and slower absorption, may probably be the cause of hyperg l ycemia. We should wait for an analog with a longer action to use in such cases.
It should be added that by re t u rn i n g to their previous intensified re g i m e n s , patients succeeded in having their pre v ious good contro l .
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A 
Medicine and the M e d i a
The B. case I n a March 1997 murder trial in Vi e n n a , Austria, a 66-year-old woman, Mrs. B., was accused of having lethally poisoned a friend by use of glibenclamide tablets. N u m e rous media re p o rts of the care f u l planning and ruthless execution of the m u rder and of Mrs. B.' s possible involvement in several other unsolved murd e r cases soon made the B. case well known t h roughout Austria. While investigations w e re ongoing and witnesses were examined, three patients were admitted to our hospital with problems related to the case.
Case 1: A 70-year-old man came into the emergency room feeling weak and complaining of polydipsia during the previous days. A history of diabetes since about 2 years and an actual fasting blood glucose of 218 mg/dl explained his condition. He had stopped taking glibenclamide for fear of deadly hypoglycemia after the media campaign surrounding the B. case. The patient was immediately treated with insulin and discharged from the hospital taking metformin twice a day after stabilization of his diabetes.
Case 2: A 69-year-old woman was admitted with a fever of 40°C. The re s u l t s of medical history, physical examination, and laboratory tests led to the diagnosis of a urinary tract infection. Her blood glucose was 458 mg/dl. Fearing death, she had stopped taking glibenclamide 3 weeks earlier after hearing the latest news on the B. case. The patient was treated with insulin but could be dismissed again on twice-daily glibenclamide after 8 days in the hospital.
Case 3: A 17-year-old girl was bro u g h t to our intensive care unit with re p o rt e d re c u rrent seizures during the 2 pre v i o u s weeks. At admission, her blood glucose was 12 mg/dl. There was no history of diabetes or antidiabetic medication, but blood glucose stayed low during the following days and continuous intravenous glucose was necessary. Though the girl denied having taken tablets, a serum sample was found definitely positive for glibenclamide by the same fore n s i c pathologist who was consultant in the B. case. Psychiatric therapy was intro d u c e d after suicide attempts in previous years w e re revealed. Pre s e n t l y, the patient is fre e f rom seizures, and blood glucose values have remained in a normal range thro u g hout follow-up.
Health care personnel, as well as the media, should be aware of the influ e n c e that nationwide announcements of medical re p o rts have on the public. The B. case is an example of the misuse of medical i n f o rmation on a broad public basis that has led to treatment errors, under-or overuse of recommended drugs, and u n n e c e s s a ry health damage, hospitalization, and cost. The media should be cautious about giving detailed information on the use of drugs in suicidal or homicidal attempts. Misinterpretation and misuse by patients and the public could be unintentional consequences. We have studied the PAI-1 gene (4G/5G) polymorphism in 177 Caucasian M e d i t e rranean type 2 diabetic patients. The sample was composed of 96 women and 81 men with a mean age of 58.9 ± 10 years. Retinopathy was present in 46.3% of the patients, 9% of them having pro l i f e r ative retinopathy. Nephropathy in the m i c roalbuminuric stage was present in 25% of type 2 diabetic patients, and 13.2% had macroalbuminuria. PAI-1 mutation was analyzed by polymerase chain re a c t i o n a m p l i fication according to Mansfield et al. (2) . The allelic and genotypic fre q u e n c i e s obtained in our population were similar to those described in Pima Indians (4G/4G 20.3%; 5G/5G 26.6%, and 4G/5G 53.1%). Clinical characteristics of diabetic subjects a c c o rding to PAI-1 genotype showed no d i ff e rences ( Table 1 ). The prevalence of either retinopathy or nephropathy did not d i ffer significantly in the three genotype g roups and remained not significant after c o n t rolling for age, sex, BMI, duration of diabetes, and glycated hemoglobin in a logistic re g ression analysis.
We did not measure PAI-1 activity in our type 2 diabetic patients; however, Nagi et al.
(1) failed to show diff e rences between the three obtained genotypes and circ u l a ting PAI-1 levels, suggesting a local action in retinal circulation to explain the association between PAI-1 genotype and re t i n o p at h y. In view of our results and the pre v i o u s published works (3), we believe that the conclusions obtained by Nagi et al. must be restricted to Pima Indians because of the variability of the genetic association studies explained, in part, by diff e rences in the ethnic origin, the population analyzed, and e n v i ronmental factors that can alter the phenotypic expression of the genes.
We conclude that it is somewhat early to confer on PAI-1 a role in the susceptibility to re t i n o p a t h y, at least in Caucasian p o p u l a t i o n s . (1, 3, 4) . However, with a recent HPLC anal y z e r, carbamylated hemoglobin does not i n t e rf e re with the measurement of HbA 1 c . The A 1 c 2.2 device (Euro g e n e t i c s-To s o h , Orleans, France) is a fully automated HPLC analyzer that uses a nonporo u s c a t i o n-exchange polymer that can separate the stable and labile fractions of HbA 1 c . The A 1 c 2.2 analyzer samples directly fro m the primary sample tube, while the Va r i a n t and Diamat devices re q u i re blood to be p rediluted and incubated at 37°C to eliminate the labile Schiff fraction.
M. BR O C H, P H D C. GU T I E R R E Z

A c k n o w l e d g m e n t s -
We compared HbA 1 c values measure d by the Diamat, Variant, and A 1 c 2.2 devices in a healthy volunteer before and after in 28.7 ± 4.6 28.6 ± 5.9 30.0 ± 6.0 NS sBP (mmHg) 149.0 ± 22.4 144.6 ± 19.9 149.9 ± 21.4 NS dBP (mmHg) 88.4 ± 13.3 83.1 ± 9.6 84.2 ± 10.4 NS HbA 1c (%) 8.7 ± 2.5 7.7 ± 2.0 7.5 ± 1.7 NS Total triglyceride (mmol/1) 2.3 ± 1.1 1.9 ± 1.2 1.8 ±. Letters v i t ro hemoglobin carbamylation. The carbamylated hemoglobin fraction was prep a red by incubating washed red blood cells (RBC) isolated from EDTA-a n t i c o a g u l a t e d blood with 5 mmol/l cyanate solution for 1 h (3) to obtain carbamylated hemoglobin at a final concentration of ϳ5%. Before RBC t reatment, the HbA 1 c levels were 5.4 (Va r iant), 5.4 (Diamat), and 5.2% (A 1 c 2 . 2 ) . After in vitro carbamylation, the HbA 1 c l e vels were 10.4, 12, and 5.4%, re s p e c t i v e l y. In the A 1 c 2.2 analyzer, carbamylated hemoglobin coelutes with the labile fraction, while the Diamat and Variant devices do not distinguish HbA 1 c f rom carbamylated hemoglobin, which is not eliminated during the preincubation step at 37°C. Because the carbamylated hemoglobin level can reach 3% in uremia (1,4), we conclude that HbA 1 c can be measure d accurately in uremic patients with the A 1 c 2.2 HPLC analyzer. Other methods, like immunoassay and affinity chro m a t o g r ap h y, can also be used for samples fro m these patients. 
DI D I E R CH E V E N N E, P H D MI C H È L E FO N F R È D E, P H D RO L A N D E DU C R O C Q, P H D MA RY L I N E CH A U F F E RT, P H
C o s t -E ffectiveness of Treatment of Type 2 D i a b e t e s
I
n a recent publication on the cost-eff e ctiveness of treating type 2 diabetes with the goal of normoglycemia (1), intensive i n t e rvention became pro g ressively less coste ffective in those who developed diabetes later in life. This conclusion might have left the reader with the impression that tre a tment of geriatric patients with type 2 diabetes is not cost-effective. It should be emphasized, as it is in the publication (Ref. 1, p. 42, column 3, 2nd paragraph) , that the analysis was of patients with newly diagnosed diabetes that developed at a m o re advanced age and not of patients who had survived diabetes until an older age. This is an important distinction. Newly diagnosed patients have low rates of complications, while patients surviving with diabetes have a high prevalence of early complications that are amenable to interv e n t i o n .
To quantify the relationship of attained age and prior duration of diabetes, analyses were done on a cohort re presentative of 85% of the incident cases of type 2 diabetes in the U.S. Standard care ( H b A 1 c 10%) was compared with intensive care implemented immediately at the time of diagnosis (as in the original study [1]) or delayed 3-18 years and implemented in those surviving with diabetes. As in the original study, intensive tre a tment was assumed to reduce HbA 1 c t o 7.2% at an incremental cost of ϳ$ 2 , 0 0 0 per person per year. For the average person aged 51 years (range 19-74) at the time of clinical diagnosis, implementation of intensive care was there f o re delayed to age 54-69 years (age range at implementation of intensive care was 77-92 for the oldest patients in the cohort).
Under these assumptions, the coste ffectiveness (C-to-E) ratio was similar whether intensive care was implemented immediately or delayed 12 years ($12,000-20,000 per quality-adjusted life-year [ Q A LY] gained). The ratio increased to ϳ$28,000 per QALY gained when implementation was delayed 15 years and then i n c reased to $32,000 per QALY gained after 18 years. Intensive treatment was most effective at reducing complications and increasing quality and quantity of life if implemented at the time of clinical diagnosis of diabetes but was also the most costly. The benefits and costs both decreased with delayed implementation, although there was still a modest benefit and a small incremental cost after a delay of 18 years.
These analyses show that intensive t reatment of patients who survive with diabetes remains cost-effective. This is in sharp contrast to the previously published analyses. For example, the C-to-E ratio for a patient newly diagnosed with clinical diabetes at age 65 years is ϳ$60,000 per Q A LY gained (Ref. 1, Fig. 2) . (In the published version of the model, it was rare for patients to live beyond age 95 years. Because there is no data on mortality for patients over age 95 years, the model has been programmed to limit survival to age 95 years. This improves the cost-eff e c t i v eness of treating diabetes diagnosed at age 65 years [range 60-70] over the value published [ϳ$100,000 per QALY gained].) H o w e v e r, the ratio is ϳ$28,000 per QALY gained for a 65-year-old person who has lived with diabetes for 14 years.
These findings have important implications for health care policy related to the t reatment of type 2 diabetes. They suggest that decisions about the intensity of diabetes treatment at a given point in the natural history of the disease should take into account the prior duration of diabetes, the status of complications, and the patient' s life expectancy (2). Attained age, per se, cannot alone be used to determine the bene fits and cost-effectiveness of interv e n t i o n .
RI C H A R D C. EA S T M A N, M D
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A 2) re p o rted that serum 1,5-AG concentrations improve rapidly after administration of the ␣-glucosidase inhibitor voglibose and concluded that 1,5-AG is superior to HbA 1 c for evaluating current glycemic status. We evaluated the clinical usefulness of 1,5-AG using another ␣-g l u c o s i d a s e i n h i b i t o r, acarbose, which is curre n t l y being prescribed for NIDDM patients with postprandial hyperglycemia (3).
T h i rt y-one patients with NIDDM (20 men and 11 women; mean age 66 ± 9 years; BMI 22.4 ± 3.3 kg/m 2 ) who were re c e i v i n g diet therapy of 25-30 kcal/kg ideal body wt w e re studied. Subjects were divided into the acarbose (300 mg) or voglibose (0.6 mg) g roup and received the respective dru g s t h ree times a day before each meal because of postprandial hyperg l y c e m i a .
After 2 weeks of treatment, 1,5-A G concentrations in the voglibose gro u p rapidly improved, consistent with the previous study (2), while those in the acarbose group did not improve (Table 1) . After 4 weeks, in both groups, the fasting plasma glucose and HbA 1 c c o n c e n t r a t i o n s w e re significantly improved, but contrary to our expectations, 1,5-AG concentrations in the acarbose group were slightly d e c re a s e d .
The mechanism of paradoxical d e c rease in 1,5-AG concentrations after t reatment with acarbose is unclear. Howe v e r, because acarbose, being diff e re n t f rom voglibose, inhibits not only maltase, ␣-dextrinase, and sucrase but also ␣-a m ylase (4), this agent may inhibit the absorption of foods (vegetables, fruits, grains, meat, and milk) containing 1,5-AG, which may have resulted in the observed discre pancy between 1,5-AG and HbA 1 c . Furt h e rm o re, metabolites of acarbose (5) might inhibit reabsorption of 1,5-AG in re n a l tubules. Further examinations are needed to clarify these points. Response to Sakane et al.
NA O K I SA K A N E, M D TO S H I H I D E YO S H I D A, M D AK I N O R I KO G U R E, M D MO T O H
S
e rum 1,5-anhydroglucitol (1,5-AG) concentration is a new clinical marker of short -t e rm glycemic cont rol in diabetes (1). Sakane et al. (2) have re p o rted the diff e rent effects of acarbose and voglibose on serum 1,5-AG concentrations. We agree with their results, which a re consistent with our previous study (3), showing that the serum 1,5-AG concentrations rapidly improved in the voglibose g roup while those in the acarbose gro u p did not improve even when HbA 1 c l e v e l was corrected 4 weeks after administration of acarbose. The results presented by Sakane et al. are consistent with the re c e n t re p o rt by Hotta et al. (4) . They showed that s e rum 1,5-AG concentrations did not change significantly during 1-week acarbose therapy, when serum fru c t o s a m i n e levels and 24-h urinary glucose excre t i o n d e c reased significantly compared with that b e f o re administration of acarbose, but i n c reased markedly 1 week after discontin- Letters uing acarbose, when serum fru c t o s a m i n e levels and 24-h urinary glucose excre t i o n did not change compared with that during acarbose therapy. 1,5-AG is actively absorbed in the intestine (5) and actively transported in the renal reabsorption p rocess (6). Daily 1,5-AG balance in nondiabetic subjects is constant (7), but seru m 1,5-AG concentration is dominantly a ffected by the amount of urinary glucose (1). On the basis of the above inform a t i o n , and as mentioned by Sakane et al., diff e rent effects of acarbose on serum 1,5-AG may be due to reduction of absorption of 1,5-AG in the intestine via inhibiting ␣-amylase, although this point remains to be c l a r i fied. On the other hand, it is unlikely that metabolites of acarbose might inhibit reabsorption of 1,5-AG in renal tubules because only 1-2% of the orally administ e red dose of acarbose is absorbed in active f o rm (8). Serum 1,5-AG is useful for evaluating current glycemic control in shortt e rm response to voglibose (3). During acarbose therapy, however, it is undere s t imated for monitoring the glycemic status and should be used in cooperation with other markers, such as fru c t o s a m i n e . (1) is most welcome and timely because it re flects pro g ress in the understanding of the etiology and pathogenesis of diabetes. I would like to comment on section III.A. of Table 1 , which a d d resses other specific types of diabetes and the genetic defects of ␤-cell function, and the accompanying text on p. 1187. While correct, the statement in the second sentence that "these forms of diabetes are f requently characterized by onset of mild h y p e rglycemia at an early age (generally b e f o re age 25 years)" may perpetuate the misconception that maturity-onset diabetes of the young (MODY) is generally characterized by mild hyperglycemia. This p e rtains to the nonpro g ressive diabetes or i m p a i red glucose tolerance associated with mutations of the glucokinase gene on c h romosome 7 (MODY2) (2). On the other hand, diabetes associated with either mutations of hepatocyte nuclear factor ( H N F ) -1␣ on chromosome 12 (MODY3) or mutations of HNF-4␣ on chro m o s o m e 20 (MODY1) are forms of the disease associated with fasting hyperglycemia at diagnosis or on follow-up in up to 80% of patients, with insulin re q u i rement in up to 30% of patients, with need for oral hypoglycemic agents in the majority of the remaining patients, and with micro v a s c ular complications in a frequency similar to that seen in type 2 diabetes (3-5). If "mild h y p e rglycemia" refers to the state at "onset," the same pertains to type 2 diabetes if the diagnosis is made at an early stage in the natural history of the disease.
KE I J I YO S H I O K
Revised Etiologic C l a s s i fication of D i a b e t e s
T he recently published compre h e n s i v e R e p o rt of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
In an etiologic classification, the use of chromosome number and gene give s c i e n t i fic precision to the loci of the mutations. In re f e rring to the phenotypic e x p ression of the various forms of these genetic defects of ␤-cell function, or to the group of these disorders (excluding mitochondrial DNA or other defects), the i d e n t i fication of the specific types by the repetitive use of chromosome and gene may be cumbersome, while the pre s e n t designations of MODY1, MODY2, MODY3, etc. . . ., or MODY, re s p e c t i v e l y, may be more convenient. Thus, in Ta b l e 1, elimination of "formerly" within the p a rentheses would be appro p r i a t e .
S i m i l a r l y, the designation of "type 1 diabetes," as used in Table 1 and text, is m o re convenient than the more exact scie n t i fic and etiologic term "Diabetes due to immune-mediated ␤-cell destru c t i o n . " 
Letters
Response to Fajans D r. Fajans (1) raises relevant and i m p o rtant issues with re g a rd to maturity-onset diabetes of the young. His suggestions are well taken, and in the next printing of the Expert Panel R e p o rt (January 1998), the appro p r i a t e changes in the document will be made.
JA M E S R. GAV I N III, M D, P H D F O R T H E EX P E RT CO M M I T T E E O N T H E DI A G N O S I S A N D CL A S S I F I C AT I O N O F DI A B E T E S ME L L I T U S
F rom the Howard Hughes Medical Institute, Chevy Chase, Mary l a n d . (1) is welcomed. It recommends a shift from the p resent phenotypic classification to one based on etiology and emphasizes earlier detection and possible pre v e n t i o n .
The diagnosis of undiff e rentiated gestational diabetes mellitus (GDM) is reviewed in detail and included as a single diagnosis in group IV of the pro p o s e d c l a s s i fication. Pregnancy provides a fre e s t ress test for latent diabetes, but it is the underlying mechanism that determ i n e s the type for the individual patient. Since t h e re are two definite etiologic types of GDM, each of which carries diff e re n t implications for the prevention and for the management of diabetes, we suggest that they be recognized in the classific ation as the following:
I V. Gestational Diabetes Mellitus (GDM)
A . Type 1 associated, leading to absolute insulin deficiency B . Type 2 associated, with pre d o m inantly insulin re s i s t a n c e A wide range of islet cell and anti-GAD antibodies has been re p o rted in patients during and after pregnancy complicated by GDM, varying with population and geography (2,3). The timing of the test may be important. However, the reliability of autoantibody testing in pre gnancy remains unknown because of the alterations in maternal immune status to p revent rejection of the fetus and placenta. The timing of the test may be i m p o rtant, and testing after the pre g n a n c y may prove more reliable. However, longt e rm (2-11 years) clinical studies (4) have re p o rted that in specific populations, up to 20% of women with previous GDM have type 1 diabetes because of markedly d e c reased plasma C-peptide response to glucose infusion. Further work is clearly needed in this area. Thus, general scre e ning with tests for anti-islet antibodies may not be cost-effective for all pre g n a n t women with GDM. However, a case can be made for testing those subjects with risk factors for this type of diabetes, particularly a family history of type 1 diabetes or autoimmune disease, and without those for type 2. Methods of arre s t i n g type 1 diabetes are effective in mice, but not yet in humans. There are now, howe v e r, ongoing trials of prevention to which patients may be re f e rred. These issues and other recommendations for women with GDM are discussed in more detail in the re p o rt of the recent 4th International Workshop Conference on Gestational Diabetes to be published shortly in Diabetes Care.
It seems equally important to re c o gnize GDM associated with type 2 diabetes. P resumptive diagnosis may be made on the basis of risk factors such as a family h i s t o ry, central obesity, particularly visceral abdominal, and the various aspects of the metabolic syndrome of insulin re s i stance. Measurement of the insulin/glucose (I/G) ratio may be useful in diff e re n t i a t i n g f rom type 1-associated GDM.
Thus, all in all, it seams reasonable to us to include the distinction of the two eti- (1), who have contributed much to our understanding of the pathophysiology of gestational diabetes mellitus (GDM), have proposed that the classification for GDM include two separate types, indicating whether the woman who has had GDM is m o re likely to go on to develop type 1 or type 2 diabetes later in life. Cert a i n l y, most women with GDM are at greatest risk for the development of type 2 diabetes. The detection of autoantibodies during and after p regnancies complicated by GDM seems to be associated with an increased risk for type 1 diabetes in the years following pre g n a n c y, as shown in several studies, including the recent publication by Füchtenbusch et al. (2) . However, as implied by Drs. Sims and Catalano, this body of knowledge is still evolving. Hopefully, increasing inform a t i o n Letters in this important field will allow us to better understand processes leading to GDM. A consecutive series of 350 obese patients (BMI Ͼ30 kg/m 2 ), aged Ն25 years and with no previous history of diabetes, who attended the Outpatient Clinic of the Section of Metabolic Diseases and Diabetology of the University of Florence (Flore n c e , Italy) after 1 September 1996 was studied. The patients (286 women, 64 men) had an age of 45.8 ± 11.9 years (mean ± SD), a BMI of 37.3 ± 7.1 kg/m 2 , and a waist-to-hip ratio of 0.85 ± 0.05 for women and 0.92 ± 0.06 for men. In all patients, fasting plasma glucose (FPG) was determined at 8:00 A.M.
ST E V E N G. GA B B E, M D F O R T H E EX P E RT CO M M I T T E EO NT H E DI
after an overnight fast. On the following day, FPG was measured again, and a standard oral glucose tolerance test (OGTT) was perf o rmed, determining plasma glucose 30, 60, 90, and 120 min after the administration of a 75-g oral glucose load (2).
Using the previous (1979) criteria of the National Diabetes Data Group (3), 69 patients (55 women, 13 men) could be c l a s s i fied as being affected by diabetes and 54 patients (41 women, 13 men) by i m p a i red glucose tolerance (IGT). Applying criteria issued by the World Health Org a n ization (WHO) in 1985 (2), the number of cases of diabetes did not change, while the number of patients classified as affected by IGT increased to 100 (79 women, 21 men).
Using the new diagnostic criteria proposed by the ADA (1), 83 cases (67 women, 16 men) of diabetes and 92 cases (72 women, 20 men) of IGT were identified. The prevalence of diabetes was 23.7 vs. 19.7% with WHO criteria (an incre a s e of 20.3%), while the prevalence of IGT was 26.2 vs. 28.5%. The diagnosis of IFG (without IGT or diabetes at the OGTT) could be established in 17 patients (14 women, 3 men), with a prevalence of 4.8%. The overall prevalence of diabetes and related abnormalities was 48.2% using WHO criteria (diabetes plus IGT), and 54.7% using the new criteria (diabetes plus IGT and IFG), with a relative incre a s e of 59.0%. If the results of the OGTT had not been considered, the diagnosis of diabetes could have been established in only 47 patients (13.4%) who had a FPG Ն1 2 6 mg/dl at both determinations instead of 83 patients (23.7%).
Although this clinical sample of obese patients is not re p resentative of the general population, the present results allow some considerations about the impact of the new diagnostic criteria and screening methods p roposed (1). The adoption of the new criteria determines a substantial rise in the estimates of prevalence of diabetes, which could have a relevant impact on management of re s o u rces for health care. In fact, the classification of a patient as being a ffected by diabetes has legal consequences on reimbursement issues in several countries, and a rise of Ͼ20% in the number of diabetic individuals can modify considerably provisions of public expenditure s .
To simplify screening pro c e d u res, it has been recommended that FPG be used for diagnosis of diabetes in unaffected individuals in clinical settings (1). It should be o b s e rved that only 56.6% of cases can be i d e n t i fied with this pro c e d u re; the stand a rd OGTT could there f o re retain its re l evance as a screening method in high-r i s k g roups. If the OGTT is applied, the pre v alence of IFG appears to be substantially lower than that of diabetes and IGT. Response to Mannucci et al.
T
he observations of Mannucci et al. (1) a re important and appreciated. They highlight some of the difficulties of d e fining precise cutoff points for the diagnosis of a clinically heterogeneous disease in which the damaging effects of the o ffending etiologic agent (glucose) occur along a continuum.
It should be noted that the new re c o mmendations do not presume to "considerably affect prevalence estimates." In fact, should there be more widespread use of a single test (i.e., fasting plasma glucose [FPG] Ն126 mg/dl, with confirmation) rather than multiple tests, overall prevalence rates of newly diagnosed disease might decre a s e (1). However, the use of a single simpler test might indeed greatly increase the number of high-risk individuals tested and result in Letters earlier diagnosis when such risks and i n c reased screenings are identified. Earlier diagnosis and intervention, including a p p ropriately increased follow-up, would be expected to lessen, not increase, the economic burden of this disease.
F i n a l l y, the authors confirm the assertion that the use of multiple testing pro c ed u res in an at-risk population will indeed i n c rease the detection and the pre v a l e n c e estimates. The Expert Committee fully acknowledged that, in some instances, the use of the oral glucose tolerance test might confer benefit for diagnostic purposes. Thus, its retention as a tool has been re c o mmended. However, it is not likely to be very useful as a widely used, reliable, userfriendly clinical tool for the broad cro s s -s e ction of individuals with diabetes in the U.S. and the world. With respect to the concern about missing individuals with diabetes because of the inability of the re c o mmended FPG cutoff point to identify 100% of cases at any point in time, it is crucial to remember that the diagnosis of the disease should be made in the context of the total patient, with appropriate consideration of all the risks associated with this disease, including family history, ethnicity, body weight and lifestyle, age, and others. Wi t h the use of such a comprehensive appro a c h in determining risk for diabetes, the less reliance we must place on the value of any single number at specific points in time. R a t h e r, the patient receives the benefit of e a r l i e r, more frequent assessment, with the numbers, however obtained, serving to c o n firm where in the dynamic spectrum of glucose tolerance a given patient may be.
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R e f e re n c e s 1 . Mannucci E, Bardini G, Ognibene A, Rotella CM: Screening for diabetes in obese patients using the new diagnostic criteria (Letter). Diabetes Care 21: 468, 1998 New Classification of D i a b e t e s T he devastating health consequences of diabetes accrue from its degenerative complications. Without these, tre a tment of diabetes would be directed solely at avoidance of symptoms of hyperg l ycemia and hypoglycemia. There is convincing evidence for type 1 diabetes and compelling evidence for type 2 diabetes that restoration of blood glucose concentrations to, or close to, normal ameliorates the m i c rovascular complications of diabetes.
The proposal by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1) to reclassify diabetes using a system based on disease etiology has considerable intrinsic appeal. Such an a p p roach inherently implies knowledge of the pathophysiology of the various subtypes of diabetes, the availability of clinical tests to identify these mechanisms, or, at least, the identification of clinically re l i a b l e s u rrogates for these mechanisms and therapeutic modalities to intervene in the pathophysiologic mechanisms. Unfort un a t e l y, such information was completely lacking from the Report .
In lieu of achieving its primary goal, the Committee could have taken a fallback position by providing guidance on the determination of degrees of insulin s e c re t o ry re s e rve and insulin re s i s t a n c e , the proximal contributors to hyperg l ycemia of diabetes.
Because they were unwilling to establish C-peptide criteria for the form e r, despite abundant published data, it is not surprising that the Committee shied away f rom recommending even ru d i m e n t a ry assessments of the latter. In what amounts to a complete intellectual re t reat in the c l a s s i fication of diabetes, the Committee comes full-face back to the National Diabetes Data Gro u p ' s (NDDG) (2) clinical and tre a t m e n t-based criteria, re f e rences to which liberally pepper the Report. The Committee provides tacit acknowledgment of the continued primacy of the NDDG classification and an abnegation of the purpose of the proposed classific a t i o n in the Report: "Thus, for the clinician and patient, it is less important to label the particular type of diabetes than it is to understand the pathogenesis of the hyperg l ycemia and to treat it effectively" (1).
For whom then, if not clinicians and patients was the classification created: academic exercise, political document? Doubtless, this enterprise was underw r i tten by funds generated by American Diabetes Association volunteers (patients and physicians) who have a right to be disappointed by this use of their hard -e a rn e d volunteer dollars.
For my part, I will continue to classify patients and characterize re s e a rch subjects with diabetes according to NDDG criteria and will insist on the same for manuscripts that I re v i e w. Response to Serv i c e T he concerns raised in Dr. Serv i c e ' s letter (1) merit thoughtful re s p o n s e . The core element of his disappointment in the Expert Committee' s eff o rt s appears to be that the committee did not p rovide recommendations for the determ ination of degrees of insulin secre t o ry re s e rve and insulin resistance, both of which are acknowledged as proximal contributors to hyperglycemia of diabetes.
Indeed, to have attempted the establishment of such criteria may have exceeded the committee' s charge. As he implies in his letter, the reason for our conc e rn and the basis for our diagnosis of diabetes is hyperglycemia. The Expert Committee confirmed levels of hyperglycemia at which the degenerative effects of diabetes begin and the etiology and/or pathogenesis of that hyperglycemia in the various subtypes of diabetes. To have cited that immune-mediated diabetes is, in its later stages, characterized by low or undetectable levels of plasma C-peptide without attempt-Letters ing to define which test and which cutoff points of the latter would qualify as low or undetectable seems no more an abnegation of responsibility than the unwillingness of this committee to propose "ru d i m e n t a ry assessments" of insulin resistance by clamp studies or frequently sampled intravenous glucose tolerance test (FSIVGTT). The tasks of establishing appropriate physiologic t h resholds and of highlighting the known basis for these cutpoints are quite diff e re n t f rom recommending standards and technical pro c e d u res that are useful in defin i n g the nature and severity of the pathophysiologic defect(s) that drive the marker of i n t e rest. While it is certainly a wort h w h i l e and even necessary undertaking, a task such as the one proposed by Dr. Serv i c e belongs to a technical review panel empowe red by some clinical laboratory oversight rather than in a classification work gro u p . Such considerations might explain why the Joint National Commission on Detection, Evaluation, and Treatment of Hypert e n s i o n listed pheochromocytoma as an import a n t cause of secondary hypertension, becuase of the underlying increased adre n e rgic tone, but did not provide recommendations for assessment of plasma catecholamines.
While it is re g rettable that Dr. Serv i c e feels that the committee engaged in a "complete intellectual re t reat," it seems clear that his expectations of the pre ro g atives of a panel of this type are somewhat d i ff e rent from the ones that have typically d e fined the constraints on classific a t i o n work groups, including the National Diabetes Data Group. As evidence continues to accrue, pro c e d u res continue to be re fined, and mechanisms become more completely understood, perhaps it will become more likely that further impro v ements will be made on our imperf e c t attempts to classify heterogeneous diseases like diabetes.
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F rom the Howard Hughes Medical Institute, Chevy Chase, Mary l a n d . (1) once again raises the important issue of whether the use of ACE inhibitors is associated with an increased risk of s e v e re hypoglycemia (2). The interpre t ation of some of the results presented in the paper can, however, be queried. The number of patients admitted to the hospital who experienced an episode of severe hypoglycemia while taking an ACE inhibitor was very small (7 of 64 patients w e re admitted with severe hypoglycemia). As a result, the adjusted and unadjusted 95% CIs for the odds ratios (ORs) associating the use of ACE inhibitors with severe hypoglycemia were very broad, making it d i fficult to determine reliably the overall e ffect size. Also, the data for several of the most important confounding factors were strikingly incomplete. For example, Ͻ50% of the patients' serum cre a t i n i n e values were available, which suggests that for some parameters only a pro p o rtion of subjects were included in the logistic re g ression analysis. In addition, the re g re ssion analysis showed that after adjustment for serum creatinine concentration, the OR linking ACE inhibitor use with risk of s e v e re hypoglycemia was not statistically s i g n i ficant. We would accept that this latter OR could become significant in a larg e r s t u d y, but we feel that overall, the authors have provided interesting, but not convincing, evidence linking the use of ACE inhibitors with severe hypoglycemia.
It is important to emphasize, as do the authors of the article, that any potential i n c rease in the risk of severe hypoglycemia that may be associated with the use of an ACE inhibitor is greatly outweighed by the other benefits of ACE inhibition in the t reatment of heart failure and diabetic n e p h ro p a t h y, and by the fact that there are many other, more important risk factors for severe hypoglycemia, such as impaire d hypoglycemia awareness (3). In addition, the authors are correct in asserting that their findings cannot be applied directly to the overwhelming majority of cases of s e v e re hypoglycemia managed in the community or in hospital emergency departments. Further studies are re q u i red to provide a definitive answer to this import a n t q u e s t i o n . (1) find that the use of ACE inhibitors in people with diabetes is associated with a three-to f o u rfold increase in the risk of hypoglycemia. They rightly criticize previous studies (2) for employing a case-contro l a p p roach, which is notoriously prone to bias, but they employ the same study design themselves. We assume, although it is not stated, that a matched analysis, using conditional logistic re g ression, was employed, because calculated unmatched odds ratios are very diff e rent from those p resented in the paper. The authors fin d that people who had experienced a hypoglycemic event were about five times more likely to be receiving hospital care; adjust-Letters o b s e rvation. We suggest that import a n t questions remain re g a rding communitybased hypoglycemia, especially in patients with type 2 diabetes.
Our study did indeed have weaknesses, which we have detailed in the art icle. However, we do not accept that our i n t e r p retation of the results was questionable. We believe that our discussion was a f a i r, reasonable, and accurate re p re s e n t ation of the data. We emphasize that our findings cannot be applied directly to the o v e rwhelming majority of cases of hypoglycemia that are managed in the community or hospital emergency depart m e n t s , but as such, our results could re p re s e n t the "tip of the iceberg" of this drug interaction. We agree that further studies are indeed re q u i red to provide a defin i t i v e answer to this important question. We reiterate that the benefits of ACE inhibitors should not be denied patients with diabetes; rather, care should be exercised, as with any intervention that may impro v e insulin sensitivity. 
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